Prospective randomized trials comparing the results of anti-CD19 CAR T cells co-stimulated with 41BB or CD28 are lacking, so it is currently not possible to determine whether either offers advantages in terms of efficacy in R/R ALL. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.